拉索昔芬用于治疗绝经后骨质疏松症的女性。 - Suppr

Suppr

超能文献

Lasofoxifene for postmenopausal women with osteoporosis.

作者信息

Katzeff Barbara S

出版信息

N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.

PMID:20568309

Abstract

摘要

相似文献

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Clin Calcium. 2004 Oct;14(10):85-93.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227-8; author reply 2228-9.

The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

Menopause. 2011 Jan;18(1):6-7. doi: 10.1097/gme.0b013e318203a46b.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2228; author reply 2228-9.

Lasofoxifene in postmenopausal women with osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):686-96. doi: 10.1056/NEJMoa0808692.

Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.

Ann Pharmacother. 2011 Apr;45(4):499-509. doi: 10.1345/aph.1P604. Epub 2011 Apr 5.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Clin Calcium. 2004 Oct;14(10):85-93.

Not all SERMs are created equal.

Menopause. 2006 May-Jun;13(3):325-7. doi: 10.1097/01.gme.0000222332.31101.42.

Another selective estrogen-receptor modulator for osteoporosis.

N Engl J Med. 2010 Feb 25;362(8):752-4. doi: 10.1056/NEJMe0912847.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

Menopause. 2006 May-Jun;13(3):377-86. doi: 10.1097/01.gme.0000188736.69617.4f.

Lasofoxifene for postmenopausal women with osteoporosis.

N Engl J Med. 2010 Jun 10;362(23):2227; author reply 2228-9. doi: 10.1056/NEJMc1003454.